ImmunityBio Stock Earnings Estimates Lifted by HC Wainwright

Key Points

• HC Wainwright raised its FY2028 EPS estimate for ImmunityBio to $0.82 from $0.54 and maintained a Buy rating with a $15 price target. It also projects EPS of $1.22 in FY2029 and $1.87 in FY2030.
• Analyst sentiment is generally favorable, with six Buy ratings and one Sell rating, producing a Moderate Buy consensus and an average price target of $16.00.
• ImmunityBio remains loss-making, reporting a quarterly EPS loss of $0.22 versus the $0.08 expected, while two directors recently sold shares under pre-arranged trading plans.

ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Equities researchers at HC Wainwright lifted their FY2028 EPS estimates for ImmunityBio in a report released on Thursday, October 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of $0.82 per share for the year, up from their prior estimate of $0.54. HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for ImmunityBio's FY2029 earnings at $1.22 EPS and FY2030 earnings at $1.87 EPS.

A number of other equities analysts also recently commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of ImmunityBio in a research note on Tuesday, October 6th. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 target price on shares of ImmunityBio in a research report on Wednesday. Finally, Jefferies Financial Group lifted their price target on shares of ImmunityBio from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $16.00.

ImmunityBio Price Performance

Shares of IBRX opened at $9.18 on Monday. The firm has a market capitalization of $9.73 billion, a price-to-earnings ratio of -9.46 and a beta of 0.02. ImmunityBio has a 1-year low of $1.95 and a 1-year high of $12.43. The company has a 50-day moving average of $8.57 and a 200 day moving average of $7.97.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to analysts' expectations of $49.70 million.

Insider Buying and Selling at ImmunityBio

In other news, Director Barry Simon sold 25,000 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total transaction of $268,750.00. Following the transaction, the director owned 2,777,788 shares of the company's stock, valued at approximately $29,861,221. This represents a 0.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the firm's stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the transaction, the director owned 100,309 shares in the company, valued at approximately $1,053,244.50. This represents a 44.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ImmunityBio

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Markowski Investments acquired a new stake in shares of ImmunityBio in the 2nd quarter worth $29,000. GAMMA Investing LLC grew its stake in ImmunityBio by 262.2% during the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company's stock worth $36,000 after buying an additional 2,756 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in ImmunityBio by 579.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company's stock worth $44,000 after buying an additional 4,907 shares during the last quarter. Western Wealth Management LLC acquired a new position in ImmunityBio during the 1st quarter valued at about $44,000. Finally, Hollencrest Capital Management acquired a new position in ImmunityBio during the 2nd quarter valued at about $44,000. 8.58% of the stock is currently owned by institutional investors.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA expands ANKTIVA’s label: The FDA approved ANKTIVA in combination with BCG for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary-only tumors, in addition to the previously covered carcinoma-in-situ population. The broader label significantly increases the drug’s addressable market and commercial potential. FDA Expands ANKTIVA Approval article
• Positive Sentiment: Durable Phase 2/3 results support ANKTIVA: Long-term QUILT-3.032 data showed a 71% complete response rate in 100 patients, median response duration of 26.6 months, and responses lasting beyond 53 months. Among responding patients, three-year cystectomy-free survival was 84%, suggesting many may avoid bladder-removal surgery. ImmunityBio Phase 3 data article
• Positive Sentiment: Analyst support remains favorable: HC Wainwright reaffirmed its Buy rating and raised its FY2027 EPS estimate to $0.10 from $0.07, while maintaining a $15 price target. Jefferies also reportedly lifted its target to $14, indicating analysts see additional upside if ANKTIVA adoption accelerates.
• Neutral Sentiment: Options activity turned unusually active: Traders purchased 26,656 call options, approximately 44% above average volume. This may reflect increased bullish speculation, but it does not guarantee sustained buying in the shares.
• Negative Sentiment: Investors remain cautious despite the clinical breakthrough: IBRX declined as traders appeared to take profits following the FDA-related rally and evaluate whether the expanded approval and strong data can translate into rapid sales growth. The company remains loss-making, and its latest reported quarter missed the consensus EPS estimate.

About ImmunityBio

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body's immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.